GGrantIndex
← Leaderboards

James J Dowling

Baylor College Of Medicine

Google Scholar ↗PubMed ↗ORCID ↗
$5,395,475
Attributed
$8,207,671
Total exposure
8
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.7M · FY2009–25
$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,207,671 · 8

By mechanism

R01$6,670,929 · 4
R21$658,644 · 2
K08$640,400 · 1
R03$237,698 · 1

Top collaborators

Most similar at Baylor College Of Medicine

Same institution · by research overlap

Others in their field

Top investigators on “Genes”

Research focus

GenesMutationTherapy DevelopmentMuscleMyopathyDisabilityChildhoodProteinsMutantMouse ModelMediatingPathogenesisIn VivoCouplingSkeletal MuscleMuscle WeaknessMutateGeneticZebrafishSarcoplasmic ReticulumProtein ExpressionSeveritiesSeverity Of IllnessEffective Therapy

Grant awards (29)

Nuclear myotubularin and its role in muscle development and the pathogenesis of X-linked myotubular myopathy$719,758
R01 · FY2025 · AR · contact PI
Environmental and Epigenetic Modifiers of Susceptibility to Malignant Hyperthermia and Environmental Heat Stroke$684,520
R01 · FY2025 · AR
Environmental and Epigenetic Modifiers of Susceptibility to Malignant Hyperthermia and Environmental Heat Stroke$740,882
R01 · FY2024 · AR
Pathophysiology and Treatment of Recessive RYR1 Related Myopathy$391,375
R01 · FY2024 · AR
AAV mediated gene knockdown of PIK3C2B as a therapeutic strategy for X-linked myotubular myopathy and fatty liver disease$125,479
R21 · FY2024 · AR
Environmental and Epigenetic Modifiers of Susceptibility to Malignant Hyperthermia and Environmental Heat Stroke$796,919
R01 · FY2023 · AR
Pathophysiology and Treatment of Recessive RYR1 Related Myopathy$403,480
R01 · FY2023 · AR
Novel gene based therapy for nemaline myopathy$347,217
R01 · FY2023 · AR · contact PI
AAV mediated gene knockdown of PIK3C2B as a therapeutic strategy for X-linked myotubular myopathy and fatty liver disease$196,642
R21 · FY2023 · AR
Pathophysiology and Treatment of Recessive RYR1 Related Myopathy$399,444
R01 · FY2022 · AR
Novel gene based therapy for nemaline myopathy$343,745
R01 · FY2022 · AR · contact PI
Pathophysiology and Treatment of Recessive RYR1 Related Myopathy$391,375
R01 · FY2021 · AR
Novel gene based therapy for nemaline myopathy$336,800
R01 · FY2021 · AR · contact PI
Pathophysiology and Treatment of Recessive RYR1 Related Myopathy$416,980
R01 · FY2020 · AR
Novel gene based therapy for nemaline myopathy$347,217
R01 · FY2020 · AR · contact PI
Novel gene based therapy for nemaline myopathy$351,217
R01 · FY2019 · AR · contact PI
Micro RNAs as biomarkers and therapeutic targets in myotubular myopathy$158,214
R21 · FY2019 · AR · contact PI
Micro RNAs as biomarkers and therapeutic targets in myotubular myopathy$20,000
R21 · FY2019 · AR · contact PI
Micro RNAs as biomarkers and therapeutic targets in myotubular myopathy$158,309
R21 · FY2018 · AR · contact PI
CCDC78 and the Pathogenesis of Centronuclear Myopathy$27,324
R03 · FY2015 · AR · contact PI
CCDC78 and the Pathogenesis of Centronuclear Myopathy$54,000
R03 · FY2014 · AR · contact PI
CCDC78 and the Pathogenesis of Centronuclear Myopathy$27,324
R03 · FY2014 · AR · contact PI
Myotubularin and the Pathogenesis of Myotubular Myopathy$128,080
K08 · FY2013 · AR · contact PI
CCDC78 and the Pathogenesis of Centronuclear Myopathy$51,300
R03 · FY2013 · AR · contact PI
Myotubularin and the Pathogenesis of Myotubular Myopathy$128,080
K08 · FY2012 · AR · contact PI
CCDC78 and the pathogenesis of centronuclear myopathy$77,750
R03 · FY2012 · AR · contact PI
Myotubularin and the Pathogenesis of Myotubular Myopathy$128,080
K08 · FY2011 · AR · contact PI
Myotubularin and the Pathogenesis of Myotubular Myopathy$128,080
K08 · FY2010 · AR · contact PI
Myotubularin and the Pathogenesis of Myotubular Myopathy$128,080
K08 · FY2009 · AR · contact PI